Vericel/$VCEL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vericel
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Ticker
$VCEL
Sector
Primary listing
Employees
357
Headquarters
Website
Vericel Metrics
BasicAdvanced
$1.8B
264.47
$0.13
1.39
-
Price and volume
Market cap
$1.8B
Beta
1.39
52-week high
$63.00
52-week low
$29.24
Average daily volume
845K
Financial strength
Current ratio
4.974
Quick ratio
4.405
Long term debt to equity
28.034
Total debt to equity
32.555
Interest coverage (TTM)
1.93%
Profitability
EBITDA (TTM)
9.508
Gross margin (TTM)
73.47%
Net profit margin (TTM)
2.85%
Operating margin (TTM)
0.48%
Effective tax rate (TTM)
2.04%
Revenue per employee (TTM)
$700,000
Management effectiveness
Return on assets (TTM)
0.18%
Return on equity (TTM)
2.59%
Valuation
Price to earnings (TTM)
264.468
Price to revenue (TTM)
7.048
Price to book
5.81
Price to tangible book (TTM)
5.92
Price to free cash flow (TTM)
-211.515
Free cash flow yield (TTM)
-0.47%
Free cash flow per share (TTM)
-0.167
Growth
Revenue change (TTM)
16.13%
Earnings per share change (TTM)
1,993.32%
3-year revenue growth (CAGR)
17.08%
10-year revenue growth (CAGR)
17.71%
3-year earnings per share growth (CAGR)
-27.60%
10-year earnings per share growth (CAGR)
-19.27%
What the Analysts think about Vericel
Analyst ratings (Buy, Hold, Sell) for Vericel stock.
Bulls say / Bears say
Vericel reported record Q1 2025 total net revenue of $52.6 million, driven by a 15% increase in MACI revenue to $46.3 million (Nasdaq).
NexoBrid net revenue jumped 207% year-over-year to $1.3 million and 31% sequentially in Q1, reflecting strong uptake in severe burn care therapies (Nasdaq).
Vericel raised its full-year 2025 profitability guidance, reaffirming 20–23% revenue growth and increasing its gross margin target to 74% and adjusted EBITDA margin to 26% (Nasdaq).
Vericel’s net loss widened to $11.2 million in Q1 2025, compared to a loss of $3.9 million in Q1 2024, underscoring continued unprofitability in the near term (Nasdaq).
Operating expenses rose to $49.1 million in Q1 2025 from $40.8 million a year earlier, a 20% increase that may pressure future margins (Nasdaq).
Epicel revenue fell to $5.0 million in Q1 2025, down from $10.7 million in the same period last year, indicating slower recovery in the burn care segment (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.
Vericel Financial Performance
Revenues and expenses
Vericel Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vericel stock?
Vericel (VCEL) has a market cap of $1.8B as of October 20, 2025.
What is the P/E ratio for Vericel stock?
The price to earnings (P/E) ratio for Vericel (VCEL) stock is 264.47 as of October 20, 2025.
Does Vericel stock pay dividends?
No, Vericel (VCEL) stock does not pay dividends to its shareholders as of October 20, 2025.
When is the next Vericel dividend payment date?
Vericel (VCEL) stock does not pay dividends to its shareholders.
What is the beta indicator for Vericel?
Vericel (VCEL) has a beta rating of 1.39. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.